×
返回 Agendas
Next Generation Feasibility: How to Predict the Unpredictable and Plan for Success
Session Chair(s)
Ira Charles Spector, PhD, MBA
Chief Executive Officer
SFA Therapeutics, Inc., United States
The use of data analytics provides a significant opportunity to change site selection from previous traditional approaches. The application of algorithmic methods to identifying sites, based on their likelihood to enroll and retain subjects and contribute valid results will be discussed.
Learning Objective : Recognize new ways to identify sites based on predictive performance parameters; Discuss potential ways to select sites that will enhance the probability of attaining the correct answer from a trial, by reducing confounding effects; Discuss how to improve study feasibility planning using statistical and other methodologies.
Speaker(s)
P Is for Patients as Well as for P Values, But Site Performance Influences Both
Ira Charles Spector, PhD, MBA
SFA Therapeutics, Inc., United States
Chief Executive Officer
Data-Driven Study Feasibility Assessment and Impact on Successful Execution of Clinical Trial Protocols
William W. Gwinn, MBA
Astellas Pharma , United States
Director, Real World Informatics, Medical Function Liaison
Feasibility for Clinical Trials in Acute Conditions: How to Predict the Unpredictable and Plan for Success
Rachel Wilder McCorkle
Quintiles Inc., United States
Associate Feasibility Manager
Next Generation Feasibility Analysis: Using a Data-Driven Approach to Ensure Accurate and Predictable Outcomes
Irina Ringler
Syneos Health, United States
注册方法
Registration override should work.